Paper39435002
Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers.
Javaid S and 6 others. RSC Adv, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers. Papers, record 39435002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39435002
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12507430 | Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. | Cell | 2002 | https://conductscience.org/library/papers/12507430 | PubMed |
| 2 | 29045389 | Molecular basis of USP7 inhibition by selective small-molecule inhibitors. | Nature | 2017 | https://conductscience.org/library/papers/29045389 | PubMed |
| 3 | 24598911 | A 2.2 Å resolution structure of the USP7 catalytic domain in a new space group elaborates upon structural rearrangements resulting from ubiquitin binding. | Acta Crystallogr F Struct Biol Commun | 2014 | https://conductscience.org/library/papers/24598911 | PubMed |
| 4 | 38468948 | Repurposing of US-FDA-approved drugs as negative modulators of ubiquitin specific protease-7 (USP7). | Heliyon | 2024 | https://conductscience.org/library/papers/38468948 | PubMed |
| 5 | 16898897 | The safety of hydroquinone. | J Eur Acad Dermatol Venereol | 2006 | https://conductscience.org/library/papers/16898897 | PubMed |
| 6 | 31986186 | Thymidine phosphorylase and prostrate cancer cell proliferation inhibitory activities of synthetic 4-hydroxybenzohydrazides: In vitro, kinetic, and in silico studies. | PLoS One | 2020 | https://conductscience.org/library/papers/31986186 | PubMed |
| 7 | 28498721 | Mechanisms of Deubiquitinase Specificity and Regulation. | Annu Rev Biochem | 2017 | https://conductscience.org/library/papers/28498721 | PubMed |
| 8 | 17853878 | The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. | Nat Protoc | 2007 | https://conductscience.org/library/papers/17853878 | PubMed |
| 9 | 9581515 | Cytotoxic activity of labdane type diterpenes against human leukemic cell lines in vitro. | Planta Med | 1998 | https://conductscience.org/library/papers/9581515 | PubMed |
| 10 | 21468693 | The multifaceted roles of USP7: new therapeutic opportunities. | Cell Biochem Biophys | 2011 | https://conductscience.org/library/papers/21468693 | PubMed |
| 11 | 36834633 | Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36834633 | PubMed |
| 12 | 35852517 | Targeting the deubiquitinase USP7 for degradation with PROTACs. | Chem Commun (Camb) | 2022 | https://conductscience.org/library/papers/35852517 | PubMed |
| 13 | 25972356 | Deubiquitinases in cancer. | Oncotarget | 2015 | https://conductscience.org/library/papers/25972356 | PubMed |
| 14 | 11741787 | Syntheses of fused heterocyclic compounds and their inhibitory activities for squalene synthase. | Bioorg Med Chem | 2002 | https://conductscience.org/library/papers/11741787 | PubMed |
| 15 | 36186590 | Highlights in USP7 inhibitors for cancer treatment. | Front Chem | 2022 | https://conductscience.org/library/papers/36186590 | PubMed |
| 16 | 32300595 | Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet? | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32300595 | PubMed |
| 17 | 19434839 | Identifying and characterizing binding sites and assessing druggability. | J Chem Inf Model | 2009 | https://conductscience.org/library/papers/19434839 | PubMed |
| 18 | 35209141 | Synthesis, Characterization, Biological Evaluation and DNA Interaction Studies of 4-Aminophenol Derivatives: Theoretical and Experimental Approach. | Molecules | 2022 | https://conductscience.org/library/papers/35209141 | PubMed |
| 19 | 37245535 | Structure and function of the highly homologous deubiquitinases ubiquitin specific peptidase 25 and 28: Insights into their pathophysiological and therapeutic roles. | Biochem Pharmacol | 2023 | https://conductscience.org/library/papers/37245535 | PubMed |
| 20 | 34474304 | Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy. | Bioorg Chem | 2021 | https://conductscience.org/library/papers/34474304 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42353625 | Screening of Natural Product-Derived USP7 Inhibitors for Cancer Therapy via Integrated Machine Learning and Molecular Simulations. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42353625 | PubMed |
| 41157055 | USP7 at the Crossroads of Ubiquitin Signaling, Cell Cycle, and Tumorigenesis. | Molecules | 2025 | https://conductscience.org/library/papers/41157055 | PubMed |
| 40472738 | The deubiquitinase USP7 stabilizes HER2 expression and promotes breast cancer progression. | Neoplasia | 2025 | https://conductscience.org/library/papers/40472738 | PubMed |
| 40165995 | Screening of Covalent Kinase Inhibitors Yields Hits for Cysteine Protease USP7 / HAUSP. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/40165995 | PubMed |
| 40001543 | Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects. | Biomolecules | 2025 | https://conductscience.org/library/papers/40001543 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MDM2 | 4193 | PubTator's text mining | https://conductscience.org/library/genes/4193 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
| USP7 | 7874 | PubTator's text mining | https://conductscience.org/library/genes/7874 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39435002
GET https://conductscience.org/api/papers/v1/39435002/references?page=2